Peroxitech Therapeutics

About:

Peroxitech Therapeutics operates as a biopharmaceutical company.

Website: https://www.peroxitech.com/

Top Investors: Xontogeny

Description:

Peroxitech Therapeutics operates as a biopharmaceutical company developing PIP-2 to reverse acute lung injury (ALI) by targeting the cytokine storm cascade process.

Total Funding Amount:

$25M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Philadelphia, Pennsylvania, United States

Founded Date:

2016-01-01

Founders:

Number of Employees:

11-50

Last Funding Date:

2022-12-13

IPO Status:

Private

Industries: